XDI offers the first federated solution for life sciences, breaking down data silos, unifying semantics, and enabling explainable decisions at scale across the enterprise.
ArisGlobal , an AI-powered technology company at the forefront of life sciences and developer of LifeSphere®, has launched XDI , its Data Intelligence Cortex. Unveiled at the company’s Breakthrough 2026 event, XDI transforms regulated life sciences data across the entire product lifecycle into continuous, explainable, and decision-ready insights.
XDI transforms data trails into a strategic advantage for life sciences companies. As organizations manage ever-increasing volumes of fragmented data across multiple systems, the challenge for central teams is not just accessing that data, but deriving consistent, explainable decisions from it. XDI connects signals across different domains, evaluates them in context, and delivers insights where decisions are made—enabling organizations to move beyond simply reacting to events and instead proactively identify risks and opportunities. Instead of requiring all data to be consolidated on a single platform, XDI brings intelligence to where the data resides .
Also Read: Angelini Pharma and Quiver Bioscience Epilepsy Drug Pact
By unifying semantics across systems, XDI enables cross-domain reasoning that is auditable, explainable and scalable – across clinical areas, pharmacovigilance, regulatory affairs, medical affairs, quality and benefit-risk functions.
“XDI is ArisGlobal’s next big step and aligns with our vision to evolve from an AI-driven company to a true technology company for data intelligence in the life sciences. The challenge for life sciences organizations in 2026 is no longer whether to adopt AI, but how to integrate AI into operations at scale and generate cross-domain data intelligence. XDI will deliver decision-ready insights by recommending actions and making the underlying rationale transparent – enabling safe, regulatory-sound decisions at scale,” explained Aman Wasan, CEO of ArisGlobal.
XDI’s initial offerings provide a unified intelligence level specifically designed for three operational domains:
- Operational intelligence for pharmacovigilance – shifts PV processes from reactive to proactive, reducing compliance effort by up to 70 to 80%* and inline QC by 75%* through continuous quality checks, combined with intelligent risk recommendations.
- Benefit-risk intelligence enables predictive, evidence-based signal management with signal detection that is more than 30% faster, a reduction of interference signals in signal workflows by up to 40%*, and a reduction in cycle time from four to six weeks to four days.
- Operational intelligence for regulatory affairs – enables regulatory affairs teams to leverage cross-domain insights and real-world data perspectives, reducing compliance effort by up to 70 to 80%* and QC by up to 75%* through continuous testing.
XDI is based on ArisGlobal’s “Trust by Design” framework. This integrates AI governance, industry commitments, and integrated auditability via ArisGlobal NavaX AI Governance, thereby ensuring regulatory resilience throughout the entire AI lifecycle.
Source: PRNewswire